Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Dec;116(6):1265-1273.
doi: 10.1097/AOG.0b013e3181fc3b1a.

Contraceptive efficacy, acceptability, and safety of C31G and nonoxynol-9 spermicidal gels: a randomized controlled trial

Anne E Burke  1 , Kurt Barnhart, Jeffrey T Jensen, Mitchell D Creinin, Terri L Walsh, Livia S Wan, Carolyn Westhoff, Michael Thomas, David Archer, Hongsheng Wu, James Liu, William Schlaff, Bruce R Carr, Diana Blithe
Affiliations
Clinical Trial

Contraceptive efficacy, acceptability, and safety of C31G and nonoxynol-9 spermicidal gels: a randomized controlled trial

Anne E Burke et al. Obstet Gynecol. 2010 Dec.

Abstract

Objective: To estimate whether a gel containing the spermicide C31G was noninferior to a commercially available product containing nonoxynol-9.

Methods: Participants were healthy, sexually active women aged 18-40 years. Measured outcomes included pregnancy rates, continuation rates, adverse events, and acceptability. The primary study outcome was contraceptive efficacy. Sample size was calculated at a 2.5% significance level using a one-sided test based on assumed 6-month pregnancy probability of 15% in the nonoxynol-9 group. Sample size was sufficient to reject, with 80% power, the null hypothesis that pregnancy probability in the C31G arm would be more than 5% higher.

Results: Nine hundred thirty-two women were randomized in the C31G group and 633 in the nonoxynol-9 group. For randomized patients with at least one episode of coitus (modified intent-to-treat group), 6-month pregnancy probabilities were 12.0% (95% confidence interval [CI] 9.3-14.7%) and 12.0% (95% CI 8.7-15.3%) for C31G and nonoxynol-9,respectively. Twelve-month pregnancy probabilities were 13.8% (95% CI 7.6-20%) for C31G and 19.8% (95% CI 10.9-28.7%) for nonoxynol-9. Two serious adverse events were deemed possibly related to study product and neither occurred in the C31G group. Three fourths of users in either group reported that they liked their assigned study product. Approximately 40% of patients discontinued prematurely for reasons other than pregnancy with 11% lost to follow-up.

Conclusion: C31G demonstrated noninferior contraceptive efficacy compared with nonoxynol-9. C31G may provide another marketable option for women seeking spermicidal contraception.

Clinical trial registration: ClinicalTrials.gov, www.ClinicalTrials.gov, NCT00274261.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Participant flow diagram
Figure 2
Figure 2
Cumulative probability of pregnancy over time among users of C31G and Conceptrol® (Kaplan-Meier method) in the modified intent-to-treat (MITT) group. The MITT group included randomized subjects reporting at least one act of coitus.
See this image and copyright information in PMC

References

    1. Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982–2002. Adv Data. 2004;(350):1–36. - PubMed
    1. Darroch JE, Frost JJ. Women’s interest in vaginal microbicides. Fam Plann Perspect. 1999;31(1):16–23. - PubMed
    1. Cook RL, Rosenberg MJ. Do spermicides containing nonoxynol-9 prevent sexually transmitted infections? A meta-analysis. Sex Transm Dis. 1998;25(3):144–150. - PubMed
    1. Stafford MK, Ward H, Flanagan A, Rosenstein IJ, Taylor-Robinson D, Smith JR, et al. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17(4):327–331. - PubMed
    1. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. COL-1492 Study Group. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360(9338):971–977. - PubMed

Publication types

Associated data